Samuel R. Denmeade
- Cancer Research top 0.5%
- Cancer, Lipids, and Metabolism 15
- Pulmonary and Respiratory Medicine top 0.2%
- Prostate Cancer Treatment and Research 135
- Prostate Cancer Diagnosis and Treatment 40
- Oncology top 1%
- Peptidase Inhibition and Analysis 21
- PARP inhibition in cancer therapy 15
-
- Hormonal and reproductive studies 35
- Molecular Biology top 1%
- RNA Interference and Gene Delivery 12
-
- Radiopharmaceutical Chemistry and Applications 44
- Co-authors
- John T. IsaacsW. Nathaniel BrennenMichael A. CarducciEmmanuel S. AntonarakisMario A. EisenbergerXiaohui LinChanning J. PallerJun Luo
- Journals
- Proceedings of the National Academy of Sciences (1 paper)Journal of Clinical Investigation (1 paper)Nature Communications (1 paper)
- Partner nations
- United StatesDenmarkBelgium
In The Last Decade
Samuel R. Denmeade
214 papers receiving 9.7k citations
Hit Papers
Peers
Comparison fields: 5 of 139
- Cancer Research 2.2k
- Pulmonary and Respiratory Medicine 4.3k
- Oncology 2.6k
- Endocrinology, Diabetes and Metabolism 1.1k
- Molecular Biology 4.4k
Countries citing papers authored by Samuel R. Denmeade
This map shows the geographic impact of Samuel R. Denmeade's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Samuel R. Denmeade with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Samuel R. Denmeade more than expected).
Fields of papers citing papers by Samuel R. Denmeade
This network shows the impact of papers produced by Samuel R. Denmeade. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Samuel R. Denmeade. The network helps show where Samuel R. Denmeade may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Samuel R. Denmeade, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 10 | |
| 2 | 2024 | 0 | |
| 3 | 2023 | 2 | |
| 4 | 2023 | 4 | |
| 5 | 2023 | 3 | |
| 6 | 2022 | 5 | |
| 7 | 2022 | 19 | |
| 8 | 2020 | 3 | |
| 9 | 2020 | 63 | |
| 10 | 2020 | 25 | |
| 11 | 2019 | 3 | |
| 12 | 2019 | 18 | |
| 13 | 2019 | 67 | |
| 14 | 2019 | 4 | |
| 15 | 2018 | 11 | |
| 16 | Challenges of conducting clinical trials of natural products to combat cancer. | 2016 | 36 |
| 17 | 2010 | 318 | |
| 18 | 2009 | 1 | |
| 19 | Prostate-Specific Membrane Antigen (PSMA) targeted prodrug “smartbombs” as therapy for prostate cancer | 2006 | 1 |
| 20 | CEP-701 and CEP-751 inhibit constitutively activated RET tyrosine kinase activity and block medullary thyroid carcinoma cell growth. | 2003 | 83 |
About Samuel R. Denmeade
Samuel R. Denmeade is a scholar working on Pulmonary and Respiratory Medicine, Endocrinology, Diabetes and Metabolism and Oncology, having authored 223 papers that have together received 9.8k indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (135 papers), Radiopharmaceutical Chemistry and Applications (44 papers), Prostate Cancer Diagnosis and Treatment (40 papers), Hormonal and reproductive studies (35 papers), Peptidase Inhibition and Analysis (21 papers), PARP inhibition in cancer therapy (15 papers), Cancer, Lipids, and Metabolism (15 papers) and RNA Interference and Gene Delivery (12 papers). The work is most often cited by research in Cancer Research (2.2k citations), Pulmonary and Respiratory Medicine (4.3k citations) and Oncology (2.6k citations). Samuel R. Denmeade has collaborated with scholars based in United States, Denmark and Belgium. Frequent co-authors include John T. Isaacs, W. Nathaniel Brennen, Michael A. Carducci, Emmanuel S. Antonarakis, Mario A. Eisenberger, Xiaohui Lin, Channing J. Paller, Jun Luo, S. Brøgger Christensen and Hao Wang. Their work appears in journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and Nature Communications.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.